澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

IMMUTEP LTD

0.377

+0.0123.29%

成交量：129.15万

成交额：48.17万

市值：5.56亿

市盈率：-8.93

高：0.380

开：0.365

低：0.365

收：0.365

52周最高：0.470

52周最低：0.222

股本：14.74亿

流通股本：12.28亿

量比：0.92

换手率：0.11%

股息：- -

股息率：- -

每股收益(TTM):-0.042

每股收益(LYR):-0.042

净资产收益率：-36.88%

总资产收益率：-22.66%

市净率：3.87

市盈率(LYR):-8.93

数据加载中...

总览公司新闻资讯公告

概念

医药生物股+0.21%

资金流向

资金流入：

资金流出：

新闻资讯

IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果

Immutep与Dr. Reddy's达成战略合作推广创新肿瘤药物Eftilagimod Alfa

IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利

IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IMM.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.377,"timestamp":1770601063890,"preClose":0.365,"halted":0,"volume":1291543,"delay":0,"changeRate":0.032876712328767155,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"交易中","change":0.012,"latestTime":"02-09 12:38:31 AEDT","open":0.365,"high":0.38,"low":0.365,"amount":481718,"amplitude":0.041096,"askPrice":0.38,"askSize":187197,"bidPrice":0.375,"bidSize":79477,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770613200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.365,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.922281,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.922281,"shares":1473721306,"dividePrice":0,"high":0.38,"amplitude":0.041096,"preClose":0.365,"low":0.365,"week52Low":0.222,"pbRate":"3.87","psRate":"110.15","week52High":0.47,"institutionHeld":0,"latestPrice":0.377,"committee":-0.403939,"eps":-0.042199,"divideRate":0,"volume":1291543,"delay":0,"ttmEps":-0.042199,"open":0.365,"prevYearClose":0.415,"prevWeekClose":0.365,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.405,"twentyDayClose":0.435,"sixtyDayClose":0.26,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132253135","title":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1173503970","title":"Immutep与Dr. Reddy's达成战略合作 推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMM.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"医药生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.002134}]}}